Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corporation is the leading global structural heart innovation company, headquartered in Irvine, California, dedicated to developing surgical and transcatheter therapies for cardiovascular disease, the leading cause of death worldwide. Founded over six decades ago, the company organizes its business into three main product groups: Transcatheter Aortic Valve Replacement (TAVR), led by the SAPIEN family of valves used to treat severe aortic stenosis (74% of 2025 net sales); Transcatheter Mitral and Tricuspid Therapies (TMTT), including the PASCAL repair system, EVOQUE tricuspid replacement system, and SAPIEN M3 mitral replacement system (9% of net sales); and Surgical Structural Heart, featuring RESILIA tissue technology products such as INSPIRIS, KONECT, and MITRIS valves (17% of net sales). The company's portfolio addresses aortic, mitral, tricuspid, and pulmonic heart valve conditions through both minimally invasive catheter-based procedures and traditional surgical approaches, with future growth targeted toward broader structural heart disease including heart failure.

Edwards markets products in approximately 100 countries, deriving 58% of 2025 net sales from the United States and 42% internationally, primarily through direct sales forces and select distributors, with no single customer representing 10% or more of net sales. Manufacturing occurs primarily in the United States, Singapore, Costa Rica, and Ireland, using fabricated materials and animal-tissue-derived components sourced under strict regulatory and safety controls, including safeguards against BSE risk. The company invests heavily in research and development (approximately 18% of 2025 sales), with a focus on clinical evidence generation, and conducts R&D primarily in the U.S. and Israel, often in partnership with research institutions and clinicians.

Edwards competes primarily against Medtronic and Abbott across its TAVR, TMTT, and Surgical segments, differentiating itself through innovation, extensive clinical trial data (including landmark studies such as EARLY TAVR), and physician education and support programs. The company operates in a heavily regulated environment, subject to oversight by the FDA, EU regulatory bodies under the Medical Device Regulation, Japan's PMDA, and other national authorities, as well as compliance obligations under laws such as the Anti-Kickback Statute, Stark Law, HIPAA, the Physician Payments Sunshine Act, the False Claims Act, and the Foreign Corrupt Practices Act. Reimbursement policies and cost-containment initiatives by governments and private payors, including CMS, significantly influence market dynamics and purchasing behavior, contributing to industry consolidation among providers and increasingly complex, large-scale customer contracts.

Edwards also emphasizes human capital management, maintaining structured talent development, succession planning, and employee engagement programs (including the myVoice survey and Speak-Up compliance channel), alongside comprehensive benefits and well-being initiatives covering mental health, physical health, and financial wellness for its global workforce.